<--- Back to Details
First PageDocument Content
Pharmaceuticals policy / Clinical research / Clinical pharmacology / Drug safety / World Health Organization / Pharmacovigilance / Uppsala Monitoring Centre / VigiBase / Adverse effect / Adverse drug reaction / Serious adverse event / Adverse event
Date: 2016-07-27 06:22:23
Pharmaceuticals policy
Clinical research
Clinical pharmacology
Drug safety
World Health Organization
Pharmacovigilance
Uppsala Monitoring Centre
VigiBase
Adverse effect
Adverse drug reaction
Serious adverse event
Adverse event

PHARMACOVIGILANCE GUIDE FOR ADVERSE DRUG REACTION MONITORING AND CAUSALITY ASSESSMENT, 2015 Post marketing Control Division,

Add to Reading List

Source URL: dra.gov.bt

Download Document from Source Website

File Size: 768,87 KB

Share Document on Facebook

Similar Documents

The EVMS Autism Spectrum Disorder Program was started by Maria Urbano, M.D., and Kathrin Hartmann, Ph.D., in 2010 to provide clinical services, research, and community outreach to individuals and their families for Autis

DocID: 1vrwY - View Document

Towards a Composite Clinical Endpoint: Identifying a Core Set of Patient and Caregiver Relevant Outcome Measures Through Qualitative Research on the Global Impact of Dravet Syndrome Rima Nabbout1, Stephane Auvin2, Cather

DocID: 1vpIt - View Document

Clinical Research Registration at Public Registry

DocID: 1vnxr - View Document

Grattoni Alessandro, Ph.D. Chairman, The Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas (USA) Dr. Grattoni’s research is dedicated to the development and clinical translation of im

DocID: 1vi9N - View Document

Clinical & Translational Research 101 Thursday, August 10, 2017 Time Location

DocID: 1vglz - View Document